Subcellular location of antitumor tripeptide-tyroserleutide in human hepatocellular carcinoma cells

Jian,Xu; Fu,Zheng; Zhang,Yanling; Che,Xuchun; Lu,Rong; Yao,Zhi

doi:10.3892/etm.2011.401

Subcellular location of antitumor tripeptide-tyroserleutide in human hepatocellular carcinoma cells

Authors:
- Xu Jian
- Zheng Fu
- Yanling Zhang
- Xuchun Che
- Rong Lu
- Zhi Yao
View Affiliations

Affiliations: Central Laboratory of General Hospital of Tianjin Medical University, Tianjin 300070, P.R. China, Department of Immunology, Tianjin Medical University, Heping, Tianjin 300070, P.R. China, Department of Biochemistry, Tianjin Medical University, Heping, Tianjin 300070, P.R. China, Shenzhen Kangzhe Pharmaceutical Co., Ltd., Shenzhen, Guandong, P.R. China
Published online on: December 1, 2011 https://doi.org/10.3892/etm.2011.401
Pages: 195-199

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tyroserleutide (YSL) is a tripeptide compound that exhibits potent antitumor activity in human tumor xenografts and tumor cell lines. However, the target of YSL on which it exerts its antitumor activity has yet to be identified. Therefore, our study aimed to investigate the subcellular location of YSL in BEL-7402 human hepatocellular carcinoma cells. Using methods of fluorescent tracing and confocal colocalization, we provide evidence that when BEL-7402 cells are treated with YSL, YSL is distributed in the cytoplasm and colocalized with the mitochondria of cancer cells. Furthermore, we observed the effect of YSL on the isolated mitochondria. Using fluorescence spectrophotometry to monitor the Δψ collapse of mitochondria isolated from BEL-7402 cells by reversion of the quenching of tetramethylrhodamine methyl ester (TMRM), we found that the isolated mitochondria reversed the quenching of the fluorescence in the solution containing TMRM and YSL. This indicates that YSL decreases the Δψ of the isolated mitochondria. Another photometry method was used to observe the effect on mitochondrial swelling when YSL acted directly on the isolated mitochondria. We reveal that YSL directly causes mitochondrial swelling in 60 min. In conclusion, this study encloses a preliminary facet of the pharmacological target of YSL, and we speculate that YSL may act directly on the mitochondria to exert its antitumor activity.

View Figures

View References

1.	Z YaoR LuJ JiaThe effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinomaPeptides2711671172200610.1016/j.peptides.2005.02.02616129512
2.	R LuJ JiaL BaoExperimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide (YSL)Cancer Chemother Pharmacol57248256200610.1007/s00280-005-0046-z16028100
3.	Z FuR LuG LiTyroserleutide tripeptide affects calcium homeostasis of human hepatocarcinoma BEL-7402 cellsSci China C Life Sci48523530200510.1360/062004-13216315604
4.	L ZhaoQ ZhaoR LuEffects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinomaJ Cell Biochem103471478200810.1002/jcb.2140917546603
5.	J YaoZ JiangW DuanInvolvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cellsBiol Pharm Bull31592597200810.1248/bpb.31.59218379047
6.	P CostantiniE JacototD DecaudinG KroemerMitochondrion as a novel target of anticancer chemotherapyJ Natl Cancer Inst9210421053200010.1093/jnci/92.13.104210880547
7.	BC TurnerT EvesY RefaeliSmall-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B cell acute lymphocytic lymphomaDNA Cell Biol27133142200810.1089/dna.2007.067518163880
8.	VR FantinP LederF16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cellsCancer Res1329336200410.1158/0008-5472.CAN-03-089914729642
9.	X JianZ FuYL ZhangSynthesis of tyroserleutide fluorescent analogue and its application on the target research of antitumor therapyProg Biochem Biophys35116111672008
10.	RC Scaduto JrLW GrotyohannMeasurement of mitochondrial membrane potential using fluorescent rhodamine derivativesBiophys J76469477199910.1016/S0006-3495(99)77214-09876159
11.	B EhrenbergV MontanaMD WeiJP WuskellLM LoewMembrane potential can be determined in individual cells from the nernstian distribution of cationic dyesBiophys J53785794198810.1016/S0006-3495(88)83158-83390520
12.	P KorgeJI GoldhaberJN WeissPhenylarsine oxide induces mitochondrial permeability transition, hypercontracture and cardiac cell deathAm J Physiol Heart Circ Physiol280H2203H2213200111299223
13.	K ZhaoGM ZhaoD WuY SoongAV BirkPW SchillerHH SzetoCell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injuryJ Biol Chem2793468234690200410.1074/jbc.M402999200
14.	JJ LemastersAL NieminenT QianThe mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagyBiochim Biophys Acta1366177196199810.1016/S0005-2728(98)00112-19714796
15.	N DiasC BailyDrugs targeting mitochondrial function to control tumor cell growthBiochem Pharmacol70112200510.1016/j.bcp.2005.03.02115907809
16.	KM DebatinD PoncetG KroemerChemotherapy: targeting the mitochondrial cell death pathwayOncogene2187868803200210.1038/sj.onc.120603912483532
17.	HC HarshaA JimenoH MolinaActivated epidermal growth factor receptor as a novel target in pancreatic cancer therapyJ Proteome Res746514658200810.1021/pr800139r18821783
18.	PO CheneJO FuchsJ BohnA small synthetic peptide which inhibits the p53-hdm2 interaction stimulates the p53 pathway in tumor cell linesJ Mol Biol299245253200010.1006/jmbi.2000.373810860736
19.	LC PapadopoulouAS TsiftsoqlouMitochondrial cytochrome c oxidase as a target site for daunomycin in K-562 cells and heart tissueCancer Res531072107819938382552
20.	V FogalL ZhangS KrajewskiE RuoslahtiMitochondrial/ cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stromaCancer Res6872107218200810.1158/0008-5472.CAN-07-675218757437
21.	R RotemA HeyfetsO FingrutD BlicksteinM ShaklaiE FlescherJasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondriaCancer Res6519841993200510.1158/0008-5472.CAN-04-309115753398
22.	JC LaiW TanL BenimetskayaP MillerM ColombiniCA SteinA pharmacological target of G3139 in melanoma cells may be the mitochondrial VDACPNAS10374947499200610.1073/pnas.060221710316648253
23.	Y TsujimotoS ShimizuRole of the mitochondrial membrane permeability transition in cell deathApoptosis12835840200710.1007/s10495-006-0525-717136322
24.	S FaivreC DelbaldoK VeraSafety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerJ Clin Oncol2445200610.1200/JCO.2005.02.219416314617